WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Author: search.filters.author.Kurt, OzgurHas files: Yes

Search Results

Now showing 1 - 7 of 7
  • Thumbnail Image
    Item
    Stool Microbiota Diversity Analysis of Blastocystis-Positive and Blastocystis-Negative Individuals
    (MDPI, 2022-01-01) Stensvold, Christen Rune; Sorland, Brede Aksdal; Berg, Rebecca P. K. D.; Andersen, Lee O'Brien; van der Giezen, Mark; Bowtell, Joanna L.; El-Badry, Ayman A.; Belkessa, Salem; Kurt, Ozgur; Nielsen, Henrik Vedel
    Blastocystis is a unicellular eukaryote found in the gastrointestinal tract of both human and other animal hosts. The clinical significance of colonic Blastocystis colonization remains obscure. In this study, we used metabarcoding and bioinformatics analyses to identify differences in stool microbiota diversity between Blastocystis-positive and Blastocystis-negative individuals (n = 1285). Alpha diversity was significantly higher in Blastocystis carriers. At phylum level, Firmicutes and Bacteroidetes were enriched in carriers, while Proteobacteria were enriched in non-carriers. The genera Prevotella, Faecalibacterium, Flavonifracter, Clostridium, Succinivibrio, and Oscillibacter were enriched in carriers, whereas Escherichia, Bacteroides, Klebsiella, and Pseudomonas were enriched in non-carriers. No difference in beta diversity was observed. Individuals with Blastocystis-positive stools appear to have gut microbiomes associated with eubiosis unlike those with Blastocystis-negative stools, whose gut microbiomes are similar to those associated with dysbiosis. The role of Blastocystis as an indicator organism and potential modulator of the gut microbiota warrants further scrutiny.
  • Thumbnail Image
    Item
    Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection
    (MDPI, 2020-01-01) Palmeira, Andreia; Sousa, Emilia; Koseler, Aylin; Sabirli, Ramazan; Goren, Tarik; Turkcuer, Ibrahim; Kurt, Ozgur; Pinto, Madalena M.; Helena Vasconcelos, M.
    SARS-CoV-2 Spike protein was predicted by molecular docking to bind the host cell surface GRP78, which was suggested as a putative good molecular target to inhibit Covid-19. We aimed to confirm that GRP78 gene expression was increased in blood of SARS-CoV-2 (+) versus SARS-CoV-2 (-) pneumonia patients. In addition, we aimed to identify drugs that could be repurposed to inhibit GRP78, thus with potential anti-SARS-CoV-2 activity. Gene expression studies were performed in 10 SARS-CoV-2 (-) and 24 SARS-CoV-2 (+) pneumonia patients. A structure-based virtual screen was performed with 10,761 small molecules retrieved from DrugBank, using the GRP78 nucleotide binding domain and substrate binding domain as molecular targets. Results indicated that GRP78 mRNA levels were approximately four times higher in the blood of SARS-CoV-2 (+) versus SARS-CoV-2 (-) pneumonia patients, further suggesting that GRP78 might be a good molecular target to treat Covid-19. In addition, a total of 409 compounds were identified with potential as GRP78 inhibitors. In conclusion, we found preliminary evidence that further proposes GRP78 as a possible molecular target to treat Covid-19 and that many clinically approved drugs bind GRP78 as an off-target effect. We suggest that further work should be urgently carried out to confirm if GRP78 is indeed a good molecular target and if some of those drugs have potential to be repurposed for SARS-CoV-2 antiviral activity.
  • Thumbnail Image
    Item
    Annexin A1 as a potential prognostic biomarker for COVID-19 disease: Case-control study
    (WILEY-HINDAWI, 2020-01-01) Canacik, Omer; Sabirli, Ramazan; Altintas, Emel; Karsli, Emre; Karis, Denizhan; Kaymaz, Buse; Sabirli, Gizem Tukenmez; Kurt, Ozgur; Koseler, Aylin
    Background Annexin A1 (AnxA1) is an important endogenous glucocoticoid protein that contributes to the suppression of inflammation by limiting the production of neutrophil and pro-inflammatory cytokines. This study aims to determine the clinical predictivity value of blood AnxA1 levels in patients with mild and severe-critical pneumonia induced by COVID-19. Methods This study employed a prospective, case-control study design and was conducted at Ankara Training and Research hospital between 10 February 2021 and 15 March 2021. A total of 74 patients (42 of whom had moderate and 32 of whom had severe/critical cases of COVID-19 disease according to World Health Organization guidelines) and 50 nonsymptomatic healthy volunteers participated in the study. Blood samples were taken from patients at the time of hospital admission, after which serum was isolated. Following the isolation of serum, AnxA1 levels were evaluated using the enzyme-linked immunosorbent assay method. Results The serum AnxA1 levels were measured as 25.5 (18.6-38.6) ng/ml in the control group, 21.2 (14.7-32) ng/ml in the moderate disease group, and 14.8 (9.7-26.8) ng/ml in the severe/critical disease group. Serum AnxA1 levels were significantly lower in the severe/critical disease group compared with the control and moderate disease groups (P = .01 and P = .0001, respectively). Using receiver operating characteristic analysis, a larger area under the curve (AUC) for the serum AnxA1 levels of the control group (AUC = 0.715, 95\% CI = 0.626-0.803
  • Thumbnail Image
    Item
    Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study
    (PERGAMON-ELSEVIER SCIENCE LTD, 2021-01-01) Karsli, Emre; Sabirli, Ramazan; Altintas, Emel; Canacik, Omer; Sabirli, Gizem Tukenmez; Kaymaz, Buse; Kurt, Ozgur; Koseler, Aylin
    Introduction: To our knowledge, the diagnostic value of the sP-Selectin level in the diagnosis of COVID-19 disease has not yet been investigated. In this study, we aimed to assess this by evaluating the relationship between sPSelectin level and the clinical severity of COVID-19 infections. Methods: A total of 80 patients (50 with mild to moderate and 30 with severe COVID-19 pneumonia), and 60 nonsymptomatic healthy volunteers participated in the study. Following serum isolation, sP-Selectin levels were assessed by Enzyme-Linked Immunosorbent Assay (ELISA) method. Results: The serum sP-Selectin level was 1.7 ng/ml in the control group (1-3.78)
  • Thumbnail Image
    Item
    Association Between S100b Levels and COVID-19 Pneumonia: A Case Control Study
    (INT INST ANTICANCER RESEARCH, 2021-01-01) Mete, Ergun; Sabirli, Ramazan; Goren, Tarik; Turkcuer, Ibrahim; Kurt, Ozgur; Koseler, Aylin
    Background/Aim: Extracellular S100b effects are mediated by the receptor for advanced glycation end products (RAGE), which is the S100b membrane receptor. RAGE belongs to the immunoglobulin superfamily of cell surface molecules and serves as a multiligand receptor and is expressed in high abundance by alveolar type I (AT-I) cells in adult pulmonary tissue. This study aimed to provide an insight into the association between the severity of COVID19 disease and serum S100b levels during admission to the emergency department (ED). Patients and Methods: A total of 64 patients (34 mild cases
  • Thumbnail Image
    Item
    Endoplasmic Reticulum Stress Markers in SARS-COV-2 Infection and Pneumonia: Case-Control Study
    (INT INST ANTICANCER RESEARCH, 2020-01-01) Koseler, Aylin; Sabirli, Ramazan; Goren, Tarik; Turkcuer, Ibrahim; Kurt, Ozgur
    Background/Aim: A novel human coronavirus, named SARS-COV-2, has recently caused thousands of deaths all around the world. Endoplasmic reticulum (ER) stress plays an important role in the development of diseases. Patients and Methods: We aimed to to investigate the relationship between ER stress markers in patients infected with SARS-COV-2 and patients with pneumonia. A total of 9 patients (4 patients diagnosed with pneumonia and 5 patients diagnosed with SARS-COV-2 infection) who admitted to the emergency Department with symptoms of pneumonia and SARS-COV-2 were included in the study. A total of 18 healthy individuals without any known chronic or acute disease and drug use were included as the healthy control group. Serum human glucose regulated protein 78 (GRP78), serum human C/EBP homologous protein (CHOP) and serum human phospho extracellular signal regulated kinase (PERK) levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: GRP78 levels were found to be significantly higher in SARS-COV-2 positive cases compared to individuals in other groups. Serum GRP78 level median value was statistically significantly higher in SARS-COV-2-positive group compared to the other groups (p=0.0003). Serum PERK level was statistically significantly higher in SARS-COV-2-positive pneumonia cases (p=0.046). Conclusion: An association was shown between GRP78 and SARS-COV-2 infection. Although a small number of patients was investigated, these results will be important and guide future treatments of SARS-COV-2.
  • Thumbnail Image
    Item
    High GRP78 levels in Covid-19 infection: A case-control study
    (PERGAMON-ELSEVIER SCIENCE LTD, 2021-01-01) Sabirli, Ramazan; Koseler, Aylin; Goren, Tarik; Turkcuer, Ibrahim; Kurt, Ozgur
    Introduction: Covid-19 infection was declared a global pandemic by WHO on March 11, 2020. GRP78 protein is known to be involved in the intrusion of numerous viruses. Our current study tries to provide some insight into the variation of GRP78 protein levels in patients with Covid-19 (-) pneumonia, Covid-19 (+) pneumonia, and CT negative Covid-19 infection in comparison to the normal population through a larger number of cases. Materials and methods: 42 patients who have Covid-19 (-) pneumonia